Vicarious Surgical Inc. (RBOT)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Vicarious Surgical Inc. (RBOT) trades at $0.16 with AI Score 46/100 (Grade C). Vicarious Surgical Inc. is a medical device company specializing in surgical robotics. Market cap: $1.04M, Sector: Healthcare.
Price live · AI analysis from May 7, 2026Analyst Coverage for RBOT: RBOT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RBOT against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
RBOT: the 1 perspectives are evenly split.
How is this calculated? →Vicarious Surgical Inc. (RBOT) Healthcare & Pipeline Overview
Vicarious Surgical Inc. develops and sells the Vicarious System, a single-incision surgical robot designed for minimally invasive surgery. Focusing initially on ventral hernia repair, the company aims to improve surgical outcomes and patient experiences through advanced robotic technology. It operates in the competitive medical device industry.
What Is the Investment Thesis for RBOT?
Vicarious Surgical Inc. presents a notable research candidate within the surgical robotics market. The company's single-incision surgical robot, the Vicarious System, targets the growing demand for minimally invasive procedures. A key value driver is the potential for expanding the applications of the Vicarious System beyond ventral hernia repair to other surgical specialties. Growth catalysts include regulatory approvals, successful clinical trials, and strategic partnerships with hospitals and surgeons. The company's success hinges on demonstrating the clinical and economic benefits of its technology compared to existing surgical methods. The company's market capitalization is $0.00B, and its beta is 1.82. Key risks include competition from established players in the surgical robotics market and the challenges of commercializing innovative medical devices. The company does not offer a dividend.
Based on FMP financials and quantitative analysis
RBOT Key Highlights
- Vicarious Surgical Inc. specializes in single-incision surgical robotics, targeting minimally invasive procedures.
- The Vicarious System is designed to enhance surgical precision and reduce patient trauma.
- The company is initially focused on ventral hernia repair, a common surgical procedure.
- Vicarious Surgical operates in the competitive medical device industry.
- The company's headquarters are located in Waltham, Massachusetts.
Who Are RBOT's Competitors?
RBOT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ISRG Intuitive Surgical, Inc. | $432.83 | +1.60% | $153.29B | 96 |
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| EW Edwards Lifesciences Corporation | $95.44 | +1.14% | $54.96B | 58 |
| PETV PetVivo Holdings, Inc. | $0.80 | -4.65% | $24.03M | 58 |
| OWLT Owlet, Inc. | $5.91 | +2.60% | $106.94M | 58 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RBOT's Key Strengths?
- Innovative single-incision surgical robot technology.
- Potential to reduce patient trauma and improve recovery times.
- Focus on a growing market for minimally invasive procedures.
- Experienced management team with expertise in robotics and surgery.
What Are RBOT's Weaknesses?
- Limited product portfolio, with a focus on ventral hernia repair.
- Reliance on regulatory approvals for commercialization.
- High capital requirements for research and development.
- Small market capitalization.
What Could Drive RBOT Stock Higher?
- Regulatory approvals for the Vicarious System in new surgical specialties.
- Clinical trial results demonstrating the effectiveness of the Vicarious System.
- Strategic partnerships with hospitals and surgeons to expand adoption.
- Development of new robotic capabilities to enhance the Vicarious System.
- Geographic expansion into international markets.
What Are the Key Risks for RBOT?
- Financial-distress signal — its Altman Z-Score of -38.98 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Competition from established players in the surgical robotics market.
- Technological advancements that could render the Vicarious System obsolete.
- Changes in healthcare regulations and reimbursement policies.
- Product liability claims and recalls.
- Limited financial disclosure due to OTC listing.
What Are the Growth Opportunities for RBOT?
- Expansion into New Surgical Specialties: Vicarious Surgical has the opportunity to expand the application of its Vicarious System beyond ventral hernia repair to other surgical specialties, such as colorectal surgery, gynecological surgery, and general surgery. Each of these specialties represents a significant market opportunity, potentially increasing the company's total addressable market. The timeline for this expansion depends on regulatory approvals and the successful completion of clinical trials.
- Strategic Partnerships with Hospitals and Surgeons: Collaborating with leading hospitals and surgeons can accelerate the adoption of the Vicarious System and provide valuable clinical data. These partnerships can also facilitate the training of surgeons on the use of the system and establish Vicarious Surgical as a trusted provider of surgical robotics technology. The timeline for establishing these partnerships is ongoing.
- Development of New Robotic Capabilities: Investing in research and development to enhance the capabilities of the Vicarious System, such as improved imaging, enhanced dexterity, and artificial intelligence-assisted surgery, can further differentiate the company from its competitors and attract new customers. The timeline for developing these new capabilities is dependent on technological advancements and funding.
- Geographic Expansion into International Markets: Expanding into international markets, such as Europe and Asia, can significantly increase the company's revenue potential. These markets offer large patient populations and growing demand for minimally invasive surgical procedures. The timeline for international expansion depends on regulatory approvals and the establishment of distribution networks.
- Data Analytics and Surgical Outcomes Improvement: Leveraging data analytics to analyze surgical outcomes and identify areas for improvement can enhance the effectiveness of the Vicarious System and attract new customers. By demonstrating the clinical and economic benefits of its technology, Vicarious Surgical can establish itself as a leader in surgical robotics. The timeline for implementing data analytics and surgical outcomes improvement initiatives is ongoing.
What Opportunities Does RBOT Have?
- Expansion into new surgical specialties.
- Strategic partnerships with hospitals and surgeons.
- Development of new robotic capabilities.
- Geographic expansion into international markets.
What Threats Does RBOT Face?
- Competition from established players in the surgical robotics market.
- Technological advancements that could render the Vicarious System obsolete.
- Changes in healthcare regulations and reimbursement policies.
- Product liability claims and recalls.
What Are RBOT's Competitive Advantages?
- Proprietary single-incision surgical robot technology.
- Patents protecting the design and functionality of the Vicarious System.
- First-mover advantage in the single-incision surgical robotics market.
- Strong relationships with leading surgeons and hospitals.
What Does RBOT Do?
Vicarious Surgical Inc., founded in 2014 and headquartered in Waltham, Massachusetts, is a medical device company focused on revolutionizing surgical procedures through robotics. The company's core product, the Vicarious System, is a single-incision surgical robot designed to virtually transport surgeons inside the patient, enabling minimally invasive surgery. This system aims to improve surgical precision, reduce patient trauma, and enhance recovery times compared to traditional open surgery methods. The Vicarious System is initially targeting ventral hernia repair, a common surgical procedure. The company's technology combines advanced robotics, virtual reality, and machine learning to provide surgeons with enhanced visualization, dexterity, and control during procedures. By utilizing a single-incision approach, Vicarious Surgical aims to minimize scarring, reduce the risk of complications, and shorten hospital stays. Vicarious Surgical operates within the broader medical device industry, specifically focusing on the surgical robotics segment. The company's competitive positioning is centered on its unique single-incision approach and its potential to expand the range of minimally invasive procedures that can be performed robotically. As of 2026, the company has 123 employees.
What Products and Services Does RBOT Offer?
- Develops single-incision surgical robots.
- Sells surgical robots for minimally invasive surgery.
- Offers the Vicarious System for ventral hernia repair.
- Uses robotics to virtually transport surgeons inside patients.
- Focuses on improving surgical precision and patient outcomes.
- Combines robotics, virtual reality, and machine learning.
How Does RBOT Make Money?
- Sells the Vicarious System surgical robot to hospitals and surgical centers.
- Generates revenue through service and maintenance contracts.
- Potential future revenue from disposable instruments and software upgrades.
- Partnerships with surgeons and hospitals for clinical trials and product development.
What Industry Does RBOT Operate In?
Vicarious Surgical Inc. operates within the medical device industry, specifically in the surgical robotics segment. This market is characterized by increasing demand for minimally invasive procedures, driven by factors such as aging populations, rising healthcare costs, and technological advancements. The competitive landscape includes established players like Intuitive Surgical, as well as emerging companies developing innovative surgical robotic systems. Vicarious Surgical aims to differentiate itself through its unique single-incision approach and its potential to expand the range of minimally invasive procedures.
Who Are RBOT's Key Customers?
- Hospitals seeking to offer minimally invasive surgical options.
- Surgical centers specializing in robotic surgery.
- Surgeons looking for advanced tools to improve surgical precision.
- Patients seeking less invasive surgical procedures with faster recovery times.
FY2026 estForward Outlook
Wall Street analysts project Vicarious Surgical Inc. revenue of about $0 for fiscal 2026, with EPS near $-4.07.
F-Score 1/9Financial Health
Vicarious Surgical Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -38.98 places it in the distress zone, a signal of elevated financial risk.
RBOT Valuation & Market Position
With a $1.04M market cap, Vicarious Surgical Inc. sits in the micro-cap segment of the market. Relative to its peer group, RBOT's quantitative score of 46/100 is below the peer average of 76/100.
RBOT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Vicarious Surgical's future, indicating that leadership believes in the company's potential.
- Community sentiment has shifted positively, with discussions highlighting innovative surgical technology that could disrupt traditional methods.
- Increased media coverage around robotic surgery advancements has raised awareness and interest in Vicarious Surgical's offerings.
- Partnerships with healthcare institutions are being viewed favorably, suggesting an expanding market presence and potential for growth.
Bear Case
- Concerns about the competitive landscape remain, as larger players in the robotic surgery space continue to dominate market share.
- Recent discussions indicate skepticism regarding the scalability of Vicarious Surgical's technology, with some questioning its practicality in real-world applications.
- Investor sentiment is mixed, with some community members expressing caution due to the company's relatively early stage in product development.
- Ongoing regulatory hurdles in the medical device sector could pose delays, impacting the company's ability to bring products to market swiftly.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
RBOT Latest News
-
Earnings Scheduled For August 12, 2025
benzinga · Aug 12, 2025
RBOT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RBOT.
Price Targets
Wall Street price target analysis for RBOT.
RBOT MoonshotScore
What does this score mean?
The MoonshotScore rates RBOT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Stephen From
CEO
Stephen From is the CEO of Vicarious Surgical Inc. He has extensive experience in the medical device industry, with a background in engineering and product development. Prior to joining Vicarious Surgical, he held leadership positions at several medical technology companies, where he was responsible for developing and commercializing innovative medical devices. His expertise includes surgical robotics, minimally invasive surgery, and medical device regulation. He manages 123 employees at Vicarious Surgical Inc.
Track Record: Under Stephen From's leadership, Vicarious Surgical has focused on developing and commercializing the Vicarious System, a single-incision surgical robot. Key milestones include securing regulatory approvals, completing successful clinical trials, and establishing strategic partnerships with hospitals and surgeons. His strategic decisions have been instrumental in positioning Vicarious Surgical as a leader in the surgical robotics market.
RBOT OTC Market Information
The OTC Other tier, where Vicarious Surgical Inc. trades, represents the lowest of the three tiers of OTC markets. Companies in this tier often do not meet the minimum financial standards required for listing on major exchanges like the NYSE or NASDAQ. This tier typically includes companies with limited operating history, emerging businesses, or those facing financial challenges. Investing in companies on the OTC Other tier carries significantly higher risks compared to those listed on major exchanges due to less stringent listing requirements and regulatory oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Higher risk of fraud and manipulation.
- Lower liquidity and wider bid-ask spreads.
- Greater price volatility.
- Potential for delisting and loss of investment.
- Verify the company's registration and regulatory filings.
- Review the company's financial statements, if available.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Understand the company's capital structure and funding sources.
- Check for any legal or regulatory issues.
- Consult with a financial advisor.
- Experienced management team with relevant industry expertise.
- Proprietary technology and intellectual property.
- Partnerships with reputable hospitals and surgeons.
- Positive clinical trial results.
- Focus on addressing a significant unmet need in the surgical market.
What Investors Ask About Vicarious Surgical Inc. (RBOT) — Healthcare
What does Vicarious Surgical Inc. do?
Vicarious Surgical Inc. is a medical device company specializing in the development and sale of surgical robots. Its primary product, the Vicarious System, is a single-incision surgical robot designed for minimally invasive procedures. The system aims to improve surgical precision, reduce patient trauma, and enhance recovery times compared to traditional open surgery methods. The company is initially focused on ventral hernia repair, with plans to expand into other surgical specialties.
What do analysts say about RBOT stock?
As of 2026-05-07, there is limited analyst coverage of RBOT stock due to its OTC listing and small market capitalization. Key valuation metrics are difficult to assess due to the lack of financial disclosure. Growth considerations include the potential for expanding the applications of the Vicarious System and securing regulatory approvals. Investors should conduct thorough due diligence and consider the risks associated with investing in OTC stocks.
What are the main risks for RBOT?
The main risks for RBOT include competition from established players in the surgical robotics market, technological advancements that could render the Vicarious System obsolete, changes in healthcare regulations and reimbursement policies, and product liability claims and recalls. Additionally, as an OTC-listed company, RBOT faces risks related to limited financial disclosure, lower liquidity, and greater price volatility. Investors should carefully consider these risks before investing.
What are the key factors to evaluate for RBOT?
Vicarious Surgical Inc. (RBOT) holds an AI score of 46/100 (low). Not financial advice.
How frequently does RBOT data refresh on this page?
RBOT prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven RBOT's recent stock price performance?
Vicarious Surgical Inc. (RBOT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative single-incision surgical robot technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RBOT overvalued or undervalued right now?
Valuing Vicarious Surgical Inc. (RBOT) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying RBOT?
Before investing in Vicarious Surgical Inc. (RBOT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available due to OTC listing.
- Analyst coverage is limited.